Bladder carcinoma: Where are the patient advocates?

Mark S. Soloway

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although bladder carcinoma is the fourth most common malignancy diagnosed in men and the eighth most common in women, little public information currently is available regarding this neoplasm. It appears that few clinicians are aware that because of the lifelong need to monitor for recurrence using cystoscopy, as well as the treatment of recurrent tumors, the cost per bladder carcinoma patient from the time of diagnosis to death is the highest among all malignancies in the U.S. In their study, Prout et al. suggest that patients with muscle-invasive bladder carcinoma, in particular those in the older age groups, may not be receiving optimal treatment. Factors that may be responsible for this are discussed.

Original languageEnglish
Pages (from-to)1559-1562
Number of pages4
JournalCancer
Volume104
Issue number8
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Urinary Bladder
Carcinoma
Neoplasms
Cystoscopy
Age Groups
Costs and Cost Analysis
Recurrence
Muscles
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bladder carcinoma : Where are the patient advocates? / Soloway, Mark S.

In: Cancer, Vol. 104, No. 8, 15.10.2005, p. 1559-1562.

Research output: Contribution to journalArticle

Soloway, Mark S. / Bladder carcinoma : Where are the patient advocates?. In: Cancer. 2005 ; Vol. 104, No. 8. pp. 1559-1562.
@article{987ca741e8a8411eb4f364a64337012c,
title = "Bladder carcinoma: Where are the patient advocates?",
abstract = "Although bladder carcinoma is the fourth most common malignancy diagnosed in men and the eighth most common in women, little public information currently is available regarding this neoplasm. It appears that few clinicians are aware that because of the lifelong need to monitor for recurrence using cystoscopy, as well as the treatment of recurrent tumors, the cost per bladder carcinoma patient from the time of diagnosis to death is the highest among all malignancies in the U.S. In their study, Prout et al. suggest that patients with muscle-invasive bladder carcinoma, in particular those in the older age groups, may not be receiving optimal treatment. Factors that may be responsible for this are discussed.",
author = "Soloway, {Mark S.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1002/cncr.21351",
language = "English",
volume = "104",
pages = "1559--1562",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Bladder carcinoma

T2 - Where are the patient advocates?

AU - Soloway, Mark S.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Although bladder carcinoma is the fourth most common malignancy diagnosed in men and the eighth most common in women, little public information currently is available regarding this neoplasm. It appears that few clinicians are aware that because of the lifelong need to monitor for recurrence using cystoscopy, as well as the treatment of recurrent tumors, the cost per bladder carcinoma patient from the time of diagnosis to death is the highest among all malignancies in the U.S. In their study, Prout et al. suggest that patients with muscle-invasive bladder carcinoma, in particular those in the older age groups, may not be receiving optimal treatment. Factors that may be responsible for this are discussed.

AB - Although bladder carcinoma is the fourth most common malignancy diagnosed in men and the eighth most common in women, little public information currently is available regarding this neoplasm. It appears that few clinicians are aware that because of the lifelong need to monitor for recurrence using cystoscopy, as well as the treatment of recurrent tumors, the cost per bladder carcinoma patient from the time of diagnosis to death is the highest among all malignancies in the U.S. In their study, Prout et al. suggest that patients with muscle-invasive bladder carcinoma, in particular those in the older age groups, may not be receiving optimal treatment. Factors that may be responsible for this are discussed.

UR - http://www.scopus.com/inward/record.url?scp=26444487269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444487269&partnerID=8YFLogxK

U2 - 10.1002/cncr.21351

DO - 10.1002/cncr.21351

M3 - Article

C2 - 16118803

AN - SCOPUS:26444487269

VL - 104

SP - 1559

EP - 1562

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -